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A B S T R A C T
Mutations in the X-linked gene methyl-CpG-binding protein 2 (MECP2) are the principal cause of Rett
syndrome, a progressive neurodevelopmental disorder aﬄicting 1 in 10,000 to 15,000 females. Studies using
hemizygous Mecp2 mouse models have revealed disruptions to some aspects of their lipid metabolism including
a partial suppression of cholesterol synthesis in the brains of mature Mecp2 mutants. The present studies
investigated whether this suppression is evident from early neonatal life, or becomes manifest at a later stage of
development. We measured the rate of cholesterol synthesis, in vivo, in the brains of male Mecp2−/y and their
Mecp2+/y littermates at 7, 14, 21, 28, 42 and 56 days of age. Brain weight was consistently lower in the
Mecp2−/y mice than in their Mecp2+/y controls except at 7 days of age. In the 7- and 14-day-old mice there
was no genotypic diﬀerence in the rate of brain cholesterol synthesis but, from 21 days and later, it was always
marginally lower in the Mecp2−/y mice than in age-matched Mecp2+/y littermates. At no age was a genotypic
diﬀerence detected in either the rate of fatty acid synthesis or cholesterol concentration in the brain. Cholesterol
synthesis rates in the liver and lungs of 56-day-old Mecp2−/y mice were normal. The onset of lower rates of
brain cholesterol synthesis at about the time closure of the blood brain barrier purportedly occurs might signify
a disruption to mechanism(s) that dictate intracellular levels of cholesterol metabolites including oxysterols
known to exert a regulatory inﬂuence on the cholesterol biosynthetic pathway.
1. Introduction
The bulk of cholesterol in the central nervous system (CNS) is
present in myelin, having been synthesized locally in the earlier stages
of development (Jurevics and Morell, 1995; Snipes and Suter, 1997).
Disruption of the cholesterol biosynthetic pathway in the brain during
development is the cause of several rare diseases (Porter and Herman,
2011). These include the Smith-Lemli-Optiz syndrome which results
from a block in the pathway at the step in which 7-dehydrocholesterol
is converted to cholesterol (Tint et al., 1994). In another part of the
biosynthetic pathway, mutations in the gene SC4mol, which encodes a
sterol-C4 methyl oxidase-like (also known as methylsterol monoox-
ygenase), result in multiple disorders including microcephaly and
delayed development (He et al., 2011). Aberrations in other pathways
involved in regulating cholesterol homeostasis in the CNS can be as
devastating as those that disrupt the biosynthetic pathway. Such is the
case in Niemann-Pick type C disease where mutations in the lysosomal
transporters NPC1 and NPC2 prevent the movement of unesteriﬁed
cholesterol from the late endosomal/lysosomal compartment into the
cytosol in every cell (Vanier, 2010). This results in a pronounced
increase in the tissue content of unesteriﬁed cholesterol and other
classes of lipids in all organs, leading to debilitation and death, most
frequently from neurodegeneration but also from pulmonary dysfunc-
tion or liver failure.
In more common neurodegenerative disorders, especially
Alzheimer's disease, there is a growing body of evidence that various
aspects of cholesterol homeostasis are awry (Bryleva et al., 2010; Orth
and Bellosta, 2012; Vance, 2012; Martin et al., 2014). This is now also
the case with Rett syndrome, a pervasive neurodevelopmental disorder
caused in most cases by loss-of-function mutations in the X-linked
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gene, methyl-CpG-binding protein 2 (MECP2) (Lombardi et al., 2015;
Lyst and Bird, 2015). Evidence for a disruption of some aspects of
cholesterol metabolism in Mecp2 deﬁciency, in particular the biosyn-
thetic pathway, has come mainly from studies in two mouse models for
this disease. Speciﬁcally, these are widely referred to as the Bird (Guy
et al., 2001) and Jaenisch (Chen et al., 2001) models, in recognition of
the investigators whose laboratories developed them. In 2008, a gene
expression analysis by microarray using whole brains from Mecp2
mutant mice of the Bird strain at 6–10 weeks of age revealed signiﬁcant
reductions in the mRNA expression levels for two of the genes that
encode proteins involved in cholesterol biosynthesis, squalene mono-
oxygenase (previously epoxidase) (Sqle), and sterol-C4-methyl-oxi-
dase-like (SC4mol) (Urdinguio et al., 2008). At about the same time,
another lab similarly reported a lower mRNA level in the cerebellum
for Cyp46a1, which encodes the enzyme that converts cholesterol to
24(S)-hydroxycholesterol (24S-OHC) exclusively in the brain (Ben-
Shachar et al., 2009). However, as noted in this publication, the loss of
Mecp2 function results in reduced expression levels of hundreds of
genes in the brain (Ben-Shachar et al., 2009). Thus, the physiological
signiﬁcance of the reductions in mRNA levels for two enzymes in the
cholesterol biosynthetic pathway was not clear, especially as another
study at that time involving a meticulous analysis of brain lipid
composition in old Mecp2 mutant mice showed that the concentration
of cholesterol across multiple regions of their CNS was the same as in
their Mecp2+/y controls (Seyfried et al., 2009). More compelling
evidence for a disruption of cholesterol metabolism in Rett syndrome
came from detailed studies by the Justice laboratory using both the
Jaeneisch and Bird mouse models, together with an array of techniques
including a mutagenesis suppressor screen (Buchovecky et al., 2013).
These experiments showed that cholesterol biosynthesis in Mecp2
mutant mice was disrupted at the squalene monoxygenase step, and
more importantly, that overcoming this defect alleviated many symp-
toms and increased longevity. One particular experiment in these
studies involving the measurement in vivo of whole brain cholesterol
synthesis showed that it was suppressed about 20% in the Mecp2−/y
mice at 56 days of age.
The primary objective of the present studies was to establish
whether the lower rate of brain cholesterol synthesis in Mecp2 mutant
mice is congenital, and if not, at what stage of development this
becomes evident.
2. Results
2.1. Mecp2−/y mice exhibited prototypical shortened lifespan and
reduced brain
As shown in Fig. 1A, the lifespan of the Mecp2−/y mice ranged
from 53 to 82 days (n=12), with the median survival time being 59
days. This agrees closely with the ﬁndings of Guy and her colleagues
(Guy et al., 2001), and thereby conﬁrms that Mecp2−/y mice of the
Bird strain have a slightly shorter lifespan than those of the Jaenisch
line (Chang et al., 2006). The data presented in the lower panels of
Fig. 1 were generated from the metabolic studies. At most age points,
the body weights of the Mecp2−/y mice were less than those of their
Mecp2+/y controls (Fig. 1B). As illustrated in Fig. 1C, from the second
week after birth, the weight of the brain in the Mecp2−/y mice was
consistently lower than in their Mecp2+/y controls. This is in agree-
ment with the ﬁndings other investigators for the both Bird and
Jaenisch models (Chen et al., 2001; Guy et al., 2001; Belichenko
et al., 2008; Nguyen et al., 2012) and also replicates the reduced brain
mass described in Rett syndrome subjects over a wide age range
(Armstrong, 2005). There was a steady age-related decline in the brain-
to-body weight ratio which, irrespective of genotype, fell from about
5.4% in the 7-day old mice to 1.9% in their 56-day old counterparts
(data not shown).
Fig. 1. Longevity of Mecp2−/y mice, and body and whole brain weights in Mecp2−/y
mice and theirMecp2+/y controls from 7 to 56 days of age. A.The lifespan data are for 19
Mecp2−/y mice and 15Mecp2+/y controls. B and C. Values are the mean ± SEM of data
from a minimum of 6 mice per group except at 14d Mecp2+/y and 21dMecp2−/y where
n=4 in both cases, and 42d Mecp2+/y where n=5. *Signiﬁcantly diﬀerent from the value
for the age-matched Mecp2+/y controls (p < 0.05).
Fig. 2. Rates of cholesterol and fatty acid synthesis, and cholesterol concentrations, in
the whole brains ofMecp2−/ymice and theirMecp2+/y controls from 7 to 56 days of age.
Cholesterol and fatty acid synthesis rates were measured in vivo using [3H]water as
described in Experimental procedures. Extracts of the same brains were used to
determine the total cholesterol concentration by gas chromatography. Values are the
mean ± SEM of data from a minimum of 6 mice per group except at 14d Mecp2+/y, 21d
Mecp2−/y, and 42d Mecp2+/y where n=4 in each case. *Signiﬁcantly diﬀerent from the
value for the age-matched Mecp2+/y controls (p < 0.05).
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2.2. Suppression of brain cholesterol synthesis inMecp2−/ymice was
not evident until the third week after birth
The data presented in Fig. 2 reveal a number of key ﬁndings
regarding sterol synthesis and lipogenesis in the developing brain of
Mecp2−/y mice and their Mecp2+/y controls. The most striking of
these is that suppression of brain cholesterol synthesis in the mutants
did not become evident until the third week after birth (Fig. 2A). No
genotypic diﬀerence in the rate of cholesterol synthesis was discernible
at 7 or 14 days postpartum, but clearly by 21 days, the rate was lower in
the mutants, and this remained the case at 28, 42 and 56 days of age. In
mice of both genotypes, the rate of cholesterol synthesis declined
markedly after 21 days, in keeping with what has been well documen-
ted for the developing brain in several species (Jurevics and Morell,
1995; Quan et al., 2003). It is particularly noteworthy that, against this
backdrop of a dramatic age-related decline in synthesis, the lower rate
of sterol synthesis in the mutant vs. wild-type mice beyond 14 days was
still clearly discernible. It should be also noted here that the lower rate
of sterol synthesis seen in the mutants at 56 days is fully consistent
with what Mecp2−/y males of the Jaenisch model, on a mixed strain
background, exhibited at this age (Buchovecky et al., 2013).
The next important ﬁnding was that, at no age, did a genotypic
diﬀerence in the rate of fatty acid synthesis in these same brains
become manifest (Fig. 2B). Furthermore, when compared to the data in
Fig. 2A, it is seen ﬁrst, that the rate of fatty acid synthesis at any age
was much higher than the rate of cholesterol synthesis, and second,
that the age-related decline in lipogenesis was much more gradual than
was the case for sterol synthesis. This dissociation partly reﬂects the
extraordinarily high demand for newly generated cholesterol for use in
myelin formation in the early stages of development (Dietschy and
Turley, 2004). Once this process begins to reach completion, the
requirement for locally synthesized cholesterol falls dramatically
(Jurevics and Morell, 1995; Quan et al., 2003). Despite the lower rate
of cholesterol synthesis in the brains of Mecp2−/y mice after 14 days,
the brain cholesterol concentration did not show a genotypic diﬀerence
at any age (Fig. 2C).
Another observation from the studies described in Fig. 2 concerns
the content of desmosterol, an immediate precursor of cholesterol in its
biosynthetic pathway, in the brains of mice at 7 and 14 days of age. An
important branch point in this pathway occurs at the lanosterol step.
Ultimately, lanosterol can be converted to cholesterol via desmosterol
in the Bloch pathway, or via 7-dehydrocholesterol in the Kandutsch-
Russell (Sharpe and Brown, 2013). It was shown decades ago that in
early development, the content of desmosterol in the CNS is quite
pronounced but then rapidly dissipates (Paoletti et al., 1965). In the
mouse brain at 7 days after birth, desmosterol accounts for about ~20
to 25% of the total sterol (Paoletti et al., 1965; Quan et al., 2003). At 14
days this ﬁgure is only ~4%, and by adulthood desmosterol accounts
for less than ~0.2%. As shown in Fig. 3, there was no genotypic
diﬀerence in the brain desmosterol concentration at 7 or 14 days, just
as there was no diﬀerence in the rate of brain cholesterol synthesis at
these two ages (Fig. 2A). Our conventional gas chromatographic
method was not suﬃciently sensitive to determine desmosterol levels
beyond 14 days of age. This requires the combined use of gas
chromatography and mass spectrometry. An earlier publication utiliz-
ing this technique in Mecp2−/y mice and their wildtype controls at 56
and 70 days showed signiﬁcantly lower brain desmosterol concentra-
tions in the mutants. That ﬁnding was consistent with the lower rates of
brain cholesterol synthesis in older Mecp2 mutant mice (Fig. 2A)
(Buchovecky et al., 2013). In the present studies, the diminished
concentration of desmosterol in the brains of the 14- vs 7-day-old
mice of both genotypes (Fig. 3) in the face of comparable high rates of
cholesterol synthesis at these two age points (Fig. 2A), may reﬂect
either an increased rate of conversion of desmosterol to cholesterol at
the later age, or/and an increased rate of cholesterol production via the
Kandutsch-Russell pathway in the 14- vs 7-day-old mice. The latter
scenario appears to exist in mice with genetically altered levels of
Cyp27A1 expression (Ali et al., 2013).
The earlier studies in 56-day-old Jaenisch mice showed that, unlike
the brain, other organs including the liver did not manifest a lower rate
of cholesterol synthesis (Buchovecky et al., 2013). Therefore, in the
current study with Bird strain mice, sterol and fatty acid synthesis were
measured in the liver and lungs of 56-day-old mutants and wildtypes.
The lungs were of particular interest because pulmonary dysfunction is
a hallmark feature of Rett syndrome, and also the expression level of
Mecp2 protein in lung tissue is very high, as it is in the mature CNS
(Shahbazian et al., 2002). The data for the liver and lungs are presented
in Fig. 4, along with those for the brain in these same mice. The brain
data are from Figs. 1 and 2, and in the case of cholesterol synthesis, are
presented on an adjusted scale so as to accent the lower rate of sterol
synthesis in the mutants (Fig. 4D). In the case of the liver (Fig. 4E) and
lungs (Fig. 4F), cholesterol synthesis rates did not show a genotypic
diﬀerence. The fatty acid synthesis rates in the brain (Fig. 4G) and
lungs (Fig. 4I) also did not vary with genotype, but in the liver, the rate
was clearly elevated in the mutants (Fig. 4H). In 56-day-old mice,
irrespective of their Mecp2 genotype, the total cholesterol concentra-
tion in the liver and lungs averaged 2.1 and 4.7 mg/g, respectively
(data not shown). Plasma total cholesterol levels were determined in
43-day-old mice. The concentrations in the Mecp2−/y mice (98.9 ±
0.8 mg/dl, n=9) were not signiﬁcantly diﬀerent than in theirMecp2+/y
controls (89.2 ± 11.2 mg/dl, n=8). A marginal increase in plasma
cholesterol concentrations was reported for 49-day-oldMecp2−/ymice
(Jaenisch allele) on a mixed strain background (129/SvEv:C57BL/
6:BALB/c) (Park et al., 2014). In 70-day-old Mecp2−/y mice (Bird
allele) on a 129S6/SvEv background, plasma total cholesterols were
about 50% higher than in their wildtype controls (Buchovecky et al.,
2013).
2.3. Mecp2−/y mice showed age-related changes in the brain mRNA
expression levels for several enzymes in the cholesterol biosynthetic
pathway but not for either Apoe or Cyp46a1
At 14 days of age, the brain cholesterol synthesis rate (nmol/h/g) in
the Mecp2−/y mice (862 ± 19) was not diﬀerent from that in their
Mecp2+/y littermates (846 ± 18) (Fig. 2A). However, at 42 days, the
rate in the Mecp2−/y mice (133 ± 5) was 21% lower than in their
Mecp2+/y littermates (168 ± 2). A comparable genotypic diﬀerence
was also found at 56 days (81 ± 8 in the Mecp2−/y mice vs. 105 ± 5 in
theMecp2+/y controls). In separate groups of mice at these same three
age points, the brain mRNA expression levels of ﬁve genes involved in
regulating cholesterol homeostasis in the CNS, including three within
Fig. 3. Desmosterol concentrations in the whole brains of Mecp2−/y mice and their
Mecp2+/y controls at 7 and 14 days of age, respectively. Values are the mean ± SEM of
data from 6 mice of each genotype at 7 days, and 4Mecp2+/y and 7Mecp2−/ymice at 14
days.
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the biosynthetic pathway, were determined. As shown in Fig. 5A, the
absence of Mecp2 in the mutants at each age was conﬁrmed. For
Hmgcr (Fig. 5B), there were clearly lower levels of mRNA expression in
the 43- and 56-day-old mice, but not in their 14-day-old counterparts.
The mRNA level for Sqle (Fig. 5C) was lower in the mutants only at 43
days. For SC4mol (Fig. 5D), the mRNA level was lower in theMecp2−/
y mice at 43 and 56 days, but this achieved statistical signiﬁcance only
at the latter age. While the focus was on genes regulating cholesterol
synthesis and degradation, the mRNA expression level of apolipopro-
tein E was also included because of the major role that it plays in the
maintenance of cholesterol homeostasis in the CNS (Vitali et al., 2014;
Zhang and Liu, 2015). The mRNA expression level for both Apoe
(Fig. 5E), and Cyp46a1 (Fig. 5F), showed no genotypic diﬀerence at
any of the three ages.
3. Discussion
Together, the present data conﬁrm and extend earlier published
ﬁndings that speciﬁc aspects of cholesterol metabolism in the CNS,
particularly the biosynthetic pathway, are disrupted in mouse models
with loss-of-function mutations in Mecp2 (Buchovecky et al., 2013). A
similar conclusion was reached in studies with primary cultured
ﬁbroblasts from Rett syndrome patients (Segatto et al., 2014). In
evaluating the pathophysiological signiﬁcance of the ﬁndings presented
here, a number of points pertaining to technical aspects of the studies
warrant comment. The ﬁrst relates to the challenge of being able to
detect genotypic diﬀerences in absolute rates of whole brain cholesterol
synthesis against a background of pronounced ontogenic changes in
this parameter. In the case of the mouse, the changes in cholesterol
synthesis rates in the CNS from early neonatal life to adulthood seen
here (Fig. 2A), and in earlier studies (Quan et al., 2003), far exceed the
magnitude of the diﬀerence in brain cholesterol synthesis rates
between Mecp2−/y and Mecp2+/y mice. The use of [3H]water to
measure the absolute cholesterol biosynthesis rate in the whole brain in
vivo provided the best strategy for answering the key question of
whetherMecp2−/ymice have lower rates of brain sterol synthesis from
birth, or manifest this feature at a later stage of development. A
limitation of this approach is that it did not yield information about
whether the lower rate of brain synthesis detected in the mutants after
14 days of age was conﬁned to speciﬁc regions or cell types in the CNS.
We have previously utilized this method to quantitate broad regional
diﬀerences in brain cholesterol synthesis in other mouse models (Xie
et al., 2000, 2003), but when the focus is on speciﬁc subcortical
structures that each represent only a small proportion of whole brain
mass, exceptionally large quantities of [3H]water are needed to obtain
measurable rates of cholesterol synthesis. The deuterated water
technique could be an alternative for such measurements (Saeed
et al., 2014b). It would probably be even more challenging to
investigate these genotypic diﬀerences in brain cholesterol synthesis
at the level of individual cell types partly because of prevailing
uncertainty about how the quantitative importance of speciﬁc cells
such as neurons as sites for cholesterol synthesis may shift with age
(Pfrieger, 2003; Björkhem and Meaney, 2004; Orth and Bellosta,
2012). Now that a Mecp2-knockout rat model has been described
(Wu et al., 2016), the larger brain mass in this species might be an
advantage for studying genotypic diﬀerences in the rate of cholesterol
synthesis in diﬀerent regions of the CNS.
Another advantage of the technique used here was that it allowed
measurement of the rate of fatty acid synthesis in the same brains
where cholesterol synthesis was determined. The biosynthetic path-
Fig. 4. Brain, liver and lung weights, and rates of cholesterol and fatty acid synthesis in these organs in Mecp2−/y mice and their Mecp2+/y controls at 56 days of age. These data are
from the same sets of 56-day-old mice described in Figs. 1B and C, and 2. Values are the mean ± SEM of data from 10Mecp2+/y controls and 7Mecp2−/y mice. *Signiﬁcantly diﬀerent
from the value for their Mecp2+/y controls (p < 0.05).
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ways for cholesterol and fatty acids share a common initiating step, and
in some instances are coordinately regulated, at least in the liver
(Gibbons, 2003). The ﬁnding that at no stage of development was a
genotypic diﬀerence in brain fatty acid synthesis detected points to a
selective, albeit modest, downregulation of sterol biosynthesis, starting
in the third postnatal week. Up to that point, not only were the rates of
cholesterol synthesis comparable in the mutants and matching wild-
types, but also there was no discernible genotypic diﬀerence in the
relative mRNA expression levels in brain of three key enzymes in the
cholesterol biosynthetic pathway. By 43-days of age, there was however
a clear trend towards lower levels of mRNA for these enzymes (Fig. 5).
Together then, these data strongly indicate that beginning in the third
postnatal week there is an adaptive suppression of brain sterol
synthesis in the Mecp2−/y mice that persists through all subsequent
stages of development. There was not a detectable impact of the lower
sterol synthesis rate on the cholesterol concentration across the brain
as a whole. This suggests there was no disruption to the supply of
cholesterol for myelin formation which underscores the fact that Rett
syndrome is a neurodevelopmental, not a neurodegenerative disorder.
One further point to be made regarding the advantage of measuring
brain cholesterol synthesis in vivo using [3H]water is that synthesis
rates in other organs can be determined. Although the technique has
yet to be applied to obtain rates of cholesterol synthesis in all the major
organs in Mecp2−/y mice and their controls at diﬀerent ages, data
presented here (Fig. 3), and earlier (Buchovecky et al., 2013), show that
the fall in brain cholesterol synthesis in the mutants is not seen in
organs like the liver and lung. Taken together then, all these ﬁndings
point to a selective suppression in cholesterol synthesis in the devel-
oping brain starting at about the time that closure of the blood brain
barrier is purported to occur in the mouse (Vorbrodt et al., 2001).
The signal responsible for causing the cholesterol synthesis rate in
the Mecp2−/y mice to fall is unknown but it could conceivably be
related to a change in the rate of transformation of cholesterol to 24(S)-
hydroxycholesterol (24S-OHC) and its subsequent transport out of the
brain for eventual conversion to bile acids in the liver. This catabolic
pathway, which is facilitated by cholesterol 24-hydroxylase (CYP46A1),
is the major route for eliminating cholesterol from the CNS, and is
therefore a key player in the maintenance of cholesterol homeostasis in
the brain (Lütjohann et al., 1996; Russell et al., 2009). There is
compelling evidence that the rate of cholesterol synthesis in the CNS
shifts in accordance with loss- or gain-of-function changes in Cyp46a1
expression. In the Cyp46a1 knockout mouse, the marked reduction in
the production of 24S-OHC and its elimination from the brain is oﬀset
by a substantial fall in cholesterol synthesis in all the major regions
(Xie et al., 2003). This ﬁne balance between synthesis and degradation
prevents the accumulation of excess unesteriﬁed cholesterol, while at
the same time ensuring that the supply of newly synthesized cholesterol
for myelin formation is not disrupted (Jurevics and Morell, 1995;
Snipes and Suter, 1997). In the converse situation where 24S-OHC
production and elimination from the brain increases, as occurs when
the blood brain barrier becomes more permeable because of defects
induced by genetic manipulation, there is a compensatory increase in
cholesterol synthesis within the brain (Saeed et al., 2014b). Such data
raise the question of what is known about Cyp46a1 expression levels
and tissue concentrations of 24S-OHC in the brains of Mecp2 mutant
mice. One study using microarray analysis of cerebella from 6-week-old
Mecp2 null mice, as well as mice with an increased expression of
human MECP2, showed a 28% fall versus a 21% increase in the relative
mRNA level for Cyp46a1 in the knockouts and transgenic mice,
respectively (Ben-Shachar et al., 2009). However, the physiological
signiﬁcance of these ﬁndings was unclear given that the expression
levels of hundreds of other genes changed in both the knockout and
transgenic mice. In a subsequent study using qRT-PCR, the Justice
laboratory (Buchovecky et al., 2013) showed that in the subcortical
regions (containing the corpus callosum, striatum, thalamus, hypotha-
lamus and hippocampus) of brains from 56-day-old mice, the expres-
Fig. 5. Relative levels of expression of mRNA for several genes involved in cholesterol
metabolism in the brains ofMecp2−/ymice and theirMecp2+/y controls at 14, 43 and 56
days of age, respectively. These analyses were carried out using whole brains as described
in Experimental procedures. The primer sequences for each of these genes are given in
Table 1.Mecp2, methyl CpG-binding protein 2;Hmgcr, 3-hydroxy-3-methylglutaryl-CoA
reductase; SC4mol, sterol-C4-methyl-oxidase-like (also known as methylsterol mono-
oxygenase with the abbreviation msmol); Sqle, squalene monooxygenase; Apoe, apoli-
poprotein E; Cyp46a1, cholesterol 24-hydroxylase. Values are the mean ± SEM of data
from 3Mecp2+/y and 5Mecp2−/ymice at 14 days, 4Mecp2+/y and 5Mecp2−/ymice at
43 days, and 6 mice of each genotype at 56 days. *Signiﬁcantly diﬀerent from the value
for the age-matched Mecp2+/y controls (p < 0.05).
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sion level of mRNA for Cyp46a1 was about 40% lower in theMecp2−/y
mice than in their Mecp2+/y controls but in 28-day-old mice the
converse was found. In the present studies, no genotypic diﬀerence in
brain Cyp46a1 mRNA levels was detected over the age span of 14–56
days.
Taken together, these various sets of data suggest that a more
extensive study of brain oxysterol metabolism in Mecp2 mutant mice
and their wildtype controls is now warranted. This should be conducted
not only at 56 days of age but also at 14 days or less before closure of
the blood brain barrier. The absolute levels of not only 24S-OHC but
other oxysterols such as 27-hydroxycholesterol should be determined
along with the plasma and liver levels of these and related oxysterols.
Inclusion of 27-hydroxycholesterol is warranted based on studies in
other models suggesting that this oxysterol exerts regulatory eﬀects on
brain cholesterol homeostasis (Ali et al., 2013; Zhang et al., 2015). Be
that as it may, these new data may help to explain why the brain
cholesterol concentration in the mutant mice is unchanged from that
seen in their matching wildtypes at all ages even though their rate of
cholesterol synthesis falls below normal beginning in the third week
after birth. Given that the eﬀect of Mecp2 dysfunction on brain
cholesterol synthesis rates is modest, it could be that this is also the
case with any genotypic diﬀerences in oxysterol concentrations that are
detected.
The ﬁnal point of emphasis centers on the incongruity between the
present ﬁnding of lower rates of brain cholesterol synthesis in the
Mecp2mutant mice and earlier data detailing the favorable response of
this model to the subcutaneous administration of ﬂuvastatin or
lovastatin, starting at the beginning of the ﬁfth or sixth week after
birth (Buchovecky et al., 2013). Such treatment resulted in multiple
beneﬁcial eﬀects including an alleviation of motor symptoms and
increased longevity. Based on these ﬁndings, a small trial evaluating
lovastatin treatment in Rett syndrome patients is now being carried out
(ClinicalTrials.gov Identiﬁer:NCT02563860). As statins were designed
to act primarily by inhibiting cholesterol synthesis, their beneﬁcial
eﬀects in the Mecp2-deﬁcient mouse presumably reﬂect other
mechanisms of action given that brain cholesterol synthesis is
already moderately suppressed in these mice (Orth and Bellosta,
2012; Martin et al., 2014). In their commentary on the ﬁndings of
Buchovecky et al., Nagy and Ackerman provide an insightful discussion
of the possible explanations for the therapeutic beneﬁt of statins in
Mecp2−/ymice, including actions at the level of membrane ﬂuidity and
function (Nagy and Ackerman, 2013). If it were ultimately
demonstrated that there is a disruption to the mechanism(s) that
dictate the steady-state levels of either 24S-OHC or 27-
hydroxycholesterol in the brain in Mecp2 deﬁciency, then an
important next step would be to determine if this could be reversed
by statin treatment using the protocols developed by the Justice
laboratory.
4. Experimental procedures
4.1. Animals
Six pairs of femaleMecp2+/− mice (Mecp2tm.1Bird) and matching
Mecp2+/y males, all on C57BL/6 background, in the age range of 3–4
weeks were purchased from The Jackson Laboratory (Bar Harbor, ME).
These were used to generate the Mecp2-/y or Mecp2+/y males for the
metabolic studies as well as new replacement breeding stock. All new-
born litters were, within 24 h, transferred to BALB/c surrogate dams
which were maintained on a low-cholesterol pelleted rodent chow diet
with a fat content of ~6% (Teklad diet 7002) (Harlan Laboratories, Inc.,
Indianapolis, IN). The pups were weaned at 22 days unless studied
before that age. Genotyping was performed by Transnetyx Inc.
(Cordova, TN) using a small notch of ear tissue taken either on the
day of study (for mice studied at 7, 14, 21 days), or at weaning (for
mice to be studied at 28, days or later). Pups to be studied at these
latter ages were weaned on to a low-cholesterol, cereal-based, chow
diet with a fat content of ~4% (Teklad diet 7001). The mice were group
housed in plastic colony cages containing wood shavings, and had
continual access to drinking water. They were kept in a light-cycled
room with 12 h of light (1200–2400 h) and darkness (0–1200 h). The
cholesterol synthesis experiments were consistently carried out in
about the last 2 h of the dark phase even though there is no diurnal
variation in the rate of cholesterol synthesis in the developing brain
(Jurevics et al., 2000). All mice were studied in the fed state. During the
running of the ontogenic studies, some litters were born on dates that
did not synchronize with the scheduling of experiments at 7 days of age
or later. The male pups from such litters were used for lifespan
measurements. All experimental protocols were approved by the
Institutional Animal Care and Use Committee of the University of
Texas Southwestern Medical Center.
4.2. Cholesterol and fatty acid synthesis
The technique employed for these measurements has been utilized
in several laboratories for measuring, in vivo, the rate of cholesterol
synthesis in either the whole brain, or speciﬁc regions of the CNS, in an
array of genetically altered mouse models (Xie et al., 2003; Halford and
Russell, 2009; Bryleva et al., 2010; Liu et al., 2010; Aqul et al., 2011;
Suzuki et al., 2013). In the current studies, whole brain cholesterol and
fatty acid synthesis were measured at 7, 14, 21, 28, 42 and 56 days of
age. Tritiated water, custom generated with an activity of 5 Ci/ml by
PerkinElmer New England Nuclear Radiochemicals, (Waltham, MA)
was diluted in sterile saline to an activity of approx 200 mCi/ml. The
mice were weighed, given an intraperitoneal injection of [3H]water
(approx 2 mCi/g body weight), and then kept in a warm environment
under a well ventilated fume hood for the next 60 min. They were then
anesthetized and exsanguinated from the inferior vena cava into a
heparinzed syringe. The brain was carefully excised, weighed, and
placed in 5 ml of ethanolic KOH. In the case of the experiment with the
56-day-old mice, the liver and lungs were also removed, rinsed in
saline, blotted and weighed. Duplicate aliquots of liver, and both lungs
combined, were added to 5 ml of ethanolic KOH. From each mouse, a
100 μl aliquot of plasma was taken through a series of dilutions for the
measurement of the plasma water speciﬁc activity. The labeled sterols
within the brain, liver and lung aliquots were extracted and quantitated
as detailed earlier (Jeske and Dietschy, 1980). The rate of cholesterol
synthesis was expressed as nmol of water incorporated into sterol per
hour per gram wet weight of tissue (nmol/h/g). It should be empha-
sized here that digitonin precipitates not only cholesterol but also
several of the intermediates in the biosynthetic pathway including
desmosterol, lathosterol and lanosterol (Dietschy and Siperstein,
1967). These three non-cholesterol sterols have been detected in the
brains of mice over a wide age range (Lütjohann et al., 2002). The
tritiated fatty acid content of the brain, liver and lung extracts was
determined as described (Repa et al., 2000). The rate of fatty acid
synthesis was expressed in the same units as for sterol synthesis.
4.3. Brain cholesterol concentrations
A portion of the same brain extract used for isolation of labeled
sterols was taken for the measurement of the total cholesterol
concentration (expressed as mg/g wet weight of tissue) by gas
chromatography using stigmastanol as an internal standard (Schwarz
et al., 1998). The fraction of tissue cholesterol present in the esteriﬁed
form could not be determined because the digestion of the brain tissue
in alcoholic KOH hydrolyzed any cholesteryl esters present. Another
point regarding the brain cholesterol concentration measurements is
that the values for the 7-day-old animals in particular, and to some
extent for the 14-day-old mice, include desmosterol, an immediate
precursor of cholesterol (Paoletti et al., 1965; Sharpe and Brown,
2013). The gas chromatographic method used for cholesterol quantita-
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tion was sensitive enough to accurately determine the concentration of
desmosterol (only at 7 and 14 days after birth), but not of other
cholesterol precursors such as lanosterol, the detection of which at any
age requires methods employing gas chromatography-mass spectro-
metry (Lütjohann et al., 2002).
4.4. Liver, lung and plasma cholesterol concentrations
The same method used for measuring brain total cholesterol
concentrations was applied to such measurements in the livers and
lungs from groups ofMecp2+/y and Mecp2−/y mice at 56 days of age,
and in the plasma in 44-day old mice of both genotypes.
4.5. Relative mRNA expression analysis
Whole brains from 14-, 43- and 56-day-old mice were quickly
frozen in liquid nitrogen. mRNA levels were measured using a Bio-Rad
CFX384 Real-Time PCR detection system. The primer sequences used
to measure mRNA levels for each gene are given in Table 1. This list of
genes does not include Cyp27A1 which encodes the production of 27-
hydroxycholesterol, a putative regulator of cholesterol synthesis in the
brain (Ali et al., 2013). This oxysterol is generated at multiple sites in
the body and readily transverses the blood-brain barrier (Saeed et al.,
2014a). All analyses were determined by the comparative cycle number
at threshold method with cyclophilin as the internal control (Valasek
and Repa, 2005). The mRNA levels were normalized to cyclophilin and
values for each mouse were then expressed relative to that obtained for
their matchingMecp2+/y controls, which, in each case, were arbitrarily
set to 1.0.
4.6. Analysis of data
All values are presented as the mean ± SEM of data from the
speciﬁed number of animals. Graphpad Prism 6.02 software
(GraphPad, San Diego, CA) was used to perform all statistical analyses.
Diﬀerences between means were tested for statistical signiﬁcance (p <
0.05) using an unpaired Student's t-test to compare the values for the
Mecp2−/y mice and their age-matched Mecp2+/y controls. The data
from the lifespan study were presented as Kaplan-Meier survival
curves.
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